BIA campaigns to improve access to new medicines in the NHS. It is vital that the UK has a supportive commercial environment for life science companies in order for patients to have access to life-saving or life-enhancing new medicines.
View more
Cell and gene therapies are transformative medicines whose full potential is only just beginning to emerge. The BIA support members working in this space ensuring growth in this sector and that these treatments can reach patients.
View more
Antimicrobial resistance (AMR) is when microbes, such as bacteria, viruses, and fungi, change over time and no longer respond to medicines designed to kill them.
View more
Animal research plays an invaluable and legally mandated part in developing medicines. It is essential - and a legal obligation – for researchers to ensure that promising new medicines are tested for safety and efficacy (i.e. having the intended effects) as far as possible before they are tested in humans.
View more